Results 121 to 130 of about 70,411 (245)

Management of Adult Patients With Isocitrate Dehydrogenase‐Mutant Gliomas in Australia: An Expert Position Statement From the Cooperative Trials Group for Neuro‐Oncology

Asia-Pacific Journal of Clinical Oncology, Volume 22, Issue 3, Page 392-403, June 2026.
Following maximal surgery when feasible, management of adult patients with isocitrate dehydrogenase (IDH)‐mutant glioma is complex and should be considered in a neuro‐oncology multidisciplinary context balancing disease control versus potential treatment‐associated toxicities. Options include continued surveillance, radiation therapy, chemotherapy, and/
Mark B. Pinkham, Hao‐Wen Sim, Rosalind L. Jeffree, Arian Lasocki, Dianne M. Legge, Frank Saran, Laveniya Satgunaseelan, Hui K. Gan   +7 more
wiley   +1 more source

Response to the Letter to the Editor Entitled "Revisiting Vincristine for FSGS: Proof-of-Mechanism Arrives, but Whom Should we Treat?" [PDF]

Kidney Int Rep
Mason WJ, Chandler JC, Gage AM, Pomeranz G, Price KL, Antonelou M, Henderson SR, Perin L, Da Sacco S, Salama AD, Long DA, Pepper RJ.   +11 more
europepmc   +1 more source

Cost‐Effectiveness Analysis of Second‐Line Lisocabtagene Maraleucel in the Treatment of Refractory or Relapsed Large B‐Cell Lymphoma

European Journal of Haematology, Volume 116, Issue 6, Page 797-805, June 2026.
ABSTRACT Objectives CAR‐T cell therapies such as lisocabtagene maraleucel (liso‐cel) have transformed the treatment of patients with second line primary refractory or early relapsed ≤ 12 months (R/R) large B‐cell lymphoma (LBCL). The objective of this study was to assess the cost‐effectiveness of liso‐cel compared to standard of care (SOC) to treat R/R
Catherine Thieblemont, Florian Colrat, Rahma Sellami, Marine Sivignon, Adrien Petel, Sébastien Branchoux, Gérard de Pouvourville   +6 more
wiley   +1 more source

First Successful Treatment Reported with Pembrolizumab in a Patient Diagnosed with Choriocarcinoma in Hungary. [PDF]

Life (Basel)
Lakatos KF, Kalmár L, Lahm E, Bíró EG, Fülöp V.   +4 more
europepmc   +1 more source

Rescue Protocols for Canine Non‐Indolent B Cell Lymphoma: A Systematic Review

Veterinary and Comparative Oncology, Volume 24, Issue 2, Page 416-419, June 2026.
ABSTRACT Canine lymphoma is a heterogenous group of diseases. The most common subtype is diffuse large B cell lymphoma (DLBCL), though definitive diagnosis beyond non‐indolent = multicentric B cell lymphoma is not often achieved in clinical practice as it requires histopathology. Most dogs respond well to standard‐of‐care multiagent chemotherapy (CHOP)
Claire Marie Cannon, Peter Bennett
wiley   +1 more source

Combinatorial chemistry identifies additional compounds that selectively inhibit DLK-dependent retrograde signaling while minimally affecting other axonal roles of DLK. [PDF]

Sci Rep
Zhang X, Jeong H, Melenski E, Gordon J, Childers WE, Thomas GM.   +5 more
europepmc   +1 more source

Mediastinal Lymphoma in 70 Dogs Treated With Lomustine or Anthracycline‐Based Multi‐Agent Chemotherapy

Veterinary and Comparative Oncology, Volume 24, Issue 2, Page 382-392, June 2026.
ABSTRACT Primary mediastinal lymphoma is rare in dogs and literature exploring this disease is limited. Therefore, the aim of this study was to describe presentation, treatment and outcome in a large cohort of dogs with mediastinal lymphoma and explore prognostic factors including chemotherapy protocol. This retrospective multi‐institute study included
Diogo Machado, Jose Alvarez Picornell, Isabel Amores‐Fuster, Sarah Benjamin, Thomas Kearns, Alenka Lavra Zajc, Yike Bing, Katie A. McNaught, Maria Sava, Charlotte Johnston, Beth Rolf, Andrew D. Yale   +11 more
wiley   +1 more source

Distortion product otoacoustic emission (DPOAE) reveals hearing loss up to 16 kHz in pediatric chemotherapy patients. [PDF]

Sci Rep
Hecker DJ, Remke MKH, Linxweiler M, Furtwängler R, Akrasu Y, Schöndorf D, Graf N, Krieter D, Oberkircher N, Schick B, Bozzato A, Simon A.   +11 more
europepmc   +1 more source

Effects of Cancer Treatment on Somatosensory and Nociceptive Processing in Children and Adolescents: A Systematic Review

Pediatric Blood &Cancer, Volume 73, Issue 5, May 2026.
ABSTRACT Chemotherapy‐induced peripheral neuropathy remains a major complication in pediatric cancer, with disrupted somatosensory and nociceptive processing being a key aspect. This review synthesizes empirical studies on alterations in somatosensory and nociceptive processing in children and adolescents with cancer.
Julia Schweiger, Laura Walz, Michael C. Frühwald, Stefan Lautenbacher, Miriam Kunz   +4 more
wiley   +1 more source

Biallelic Inactivation of NSD1 Associated With Carcinogenesis in Sotos Syndrome

Pediatric Blood &Cancer, Volume 73, Issue 6, June 2026.
Nicholas A. Borja, Anuja Sule, Katie Ann McMullen, Aditi Dhir, Matthew D. Hall, Heather J. McCrea, Sakir Humayun Gultekin, Mustafa Tekin, Bradley Gampel   +8 more
wiley   +1 more source